Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

55.66 +2.13 (+3.98%)

Streaming Delayed Price Updated: 12:50 PM EDT, May 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗

May 25, 2026

Are there significant gains ahead for one (or both) of these innovative biotechs?

Via The Motley Fool

The Best Stocks to Invest $3,000 In Right Now ↗

May 19, 2026

Not every high-potential name costs a fortune to step into.

Via The Motley Fool

CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms ↗

May 15, 2026

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple...

Via MarketBeat

Topics Intellectual Property

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗

May 11, 2026

The biotech's innovative platform could pay off.

Via The Motley Fool

Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗

May 06, 2026

The market wasn't impressed by its latest quarterly update.

Via The Motley Fool

Topics Initial Public Offering

Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗

April 30, 2026

These companies are leaders in their fields.

Via The Motley Fool

What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗

April 30, 2026

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Via The Motley Fool

Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗

April 30, 2026

This particular player has seen its yield rise in recent years.

Via The Motley Fool

3 Growth Stocks That Could Generate 10X Returns ↗

April 29, 2026

These stocks come with risk, but they also have some exciting long-term growth opportunities.

Via The Motley Fool

Topics Cannabis Law Enforcement

3 Biotech Stocks That Could Benefit from the Patent Cliff ↗

April 27, 2026

Via MarketBeat

Topics Intellectual Property

CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? ↗

April 21, 2026

We'll know more about the company's medium-term prospects by the end of the year.

Via The Motley Fool

2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗

April 13, 2026

The company's strong cash position gives investors confidence in the gene-editing stock.

Via The Motley Fool

This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area ↗

April 08, 2026

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

Via The Motley Fool

Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position? ↗

April 07, 2026

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.

Via The Motley Fool

Topics ETFs

CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗

March 23, 2026

The gene-editing stock has been in a tailspin of late.

Via The Motley Fool

Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026

March 20, 2026

As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant...

Via Finterra

Topics Intellectual Property

Is CRISPR Therapeutics Stock a Buy Now? ↗

March 20, 2026

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Via The Motley Fool

3 Monster Stocks to Hold for the Next 10 Years ↗

March 10, 2026

They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies.

Via The Motley Fool

Topics Artificial Intelligence

This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday ↗

March 10, 2026

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

Via The Motley Fool

Why Is CRSP Stock Falling Pre-Market Today? ↗

March 10, 2026

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.

Via Stocktwits

RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models ↗

March 10, 2026

The firm believes the new lineup could significantly expand Rivian's addressable EV market.

Via Stocktwits

Topics Electric Vehicles

Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗

March 04, 2026

These two biotechs have a lot in common. Their differences are even more pronounced.

Via The Motley Fool

Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗

March 02, 2026

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

March 01, 2026

Could these three stocks be Cathie Wood's next big winners?

Via The Motley Fool

Topics ETFs

Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? ↗

February 20, 2026

The past few years have been challenging for the biotech.

Via The Motley Fool

The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗

February 20, 2026

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Via The Motley Fool

Topics ETFs

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

These biotech companies have catalysts ahead.

Via The Motley Fool

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗

February 19, 2026

Via MarketBeat

Should You Buy Shares of CRISPR Therapeutics in February? ↗

February 18, 2026

The company could finally be ready to deliver on years of promise.

Via The Motley Fool

The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗

February 13, 2026

2026 could be a big year for this company.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.